Table 2.
The Percentage of Evaluated Patients without ADT, GI and GU Adverse Effects and PSA Concentration of Evaluated Patients During FU
| RT end | 1 month | 4 months | 8 months | 14 months | 20 months | 26 months | 32 months | 38 months | |
|---|---|---|---|---|---|---|---|---|---|
| N of observed patients | 400 | 250 | 343 | 303 | 242 | 143 | 87 | 40 | 14 |
| No ADT [%] | 41.8 | 61.5 | 56.3 | 75.7 | 82.2 | 86.1 | 97.7 | 95 | 100 |
| GI 0 [%] | 90.7 | 89.6 | 94.4 | 95 | 97.5 | 93.7 | 96.5 | 100 | 92.9 |
| GI 1 [%] | 8.8 | 8.4 | 4.7 | 4.3 | 2.1 | 5.6 | 2.3 | - | 7.1 |
| GI 2 [%] | 0.5 | 1.6 | 0.6 | 0.7 | 0.4 | 0.7 | 1.2 | - | - |
| GI 3 [%] | - | 0.4 | 0.3 | - | - | - | - | - | - |
| GU 0 [%] | 77.5 | 70.1 | 90.1 | 95.7 | 91.3 | 96.5 | 95.3 | 92.5 | 100 |
| GU 1 [%] | 16 | 25.5 | 7 | 3.6 | 7.1 | 2.1 | 2.3 | 5 | - |
| GU 2 [%] | 6 | 4 | 2.9 | 0.7 | 1.6 | 1.4 | 2.4 | 2.5 | - |
| GU 3 [%] | 0.5 | 0.4 | - | - | - | - | - | - | - |
| PSA mean | 3.8 | 1.8 | 0.9 | 0.7 | 0.7 | 0.5 | 0.5 | 0.4 | 0.2 |
| PSA median | 2.3 | 0.8 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
ADT, Androgen Deprivation Therapy; GI, Gastro-Intestinal; GU, Genito-Urinary; PSA, Prostate Specific Antigen; FU, Follow-Up